巨细胞病毒原发感染的产前筛查:成本-效用模型
该研究基于加拿大医疗体系视角构建决策分析模型,比较孕早期普遍血清学筛查、高危孕妇筛查及无血清学筛查三种策略的成本效用。结果显示普遍筛查在96.36%的模拟中为最具成本效用选项,每年可检出152例孕妇原发CMV感染并预防29例先天性CMV感染。
要点
- 普遍血清学筛查的效用为-0.42 QALY损失,优于高危筛查(-0.63)和无筛查(-0.87)。
- 敏感性分析显示普遍筛查在所有情景下最具成本效用。
- 普遍筛查每年可检出152例孕妇原发CMV感染并预防29例先天性CMV感染。
核心结论
- 研究结果支持采用基于人群的产前筛查方案以预防先天性CMV感染。
研究设计与样本
- 决策分析模型,从医疗体系视角比较三种策略:孕早期普遍血清学筛查、仅高危孕妇筛查(两者均包括原发感染时抗病毒预防)及由胎儿形态超声触发血清学检测(无CMV血清学筛查)。
- 假设人群为80 000名孕妇,数据来源于已发表文献、当地医院及国家保险数据。
主要发现
- 普遍血清学筛查的效用为-0.42 QALY损失,高危孕妇筛查为-0.63 QALY损失,无筛查为-0.87 QALY损失。
- 敏感性分析表明,无论原发感染发病率、羊膜腔穿刺接受度及抗病毒预防疗效如何,普遍筛查均为最具成本效用策略。
- 蒙特卡洛分析中,普遍血清学筛查在96.36%的模拟中为最具成本效用选项。
- 普遍血清学筛查每年可检出152例孕妇原发CMV感染,并预防29例先天性CMV感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Congenital cytomegalovirus (CMV) infection is a major cause of deafness and neurodevelopmental disability in children. Our objective was to assess the cost utility of first-trimester serological CMV screening, compared to screening of high-risk pregnancies and no serological screening. DESIGN: A decision-analytic model was created to compare the cost utility of three strategies from a healthcare sector perspective: universal first-trimester serological screening, screening only of high-risk pregnant women (both including antiviral prophylaxis in cases of primary infection) and serological testing triggered by foetal morphological ultrasound (no CMV serological screening). SETTING: Canada. POPULATION: Hypothetical population of 80 000 pregnant women. METHODS: Probability, expected values and cost estimates were derived from published literature and local hospital and national insurance data. MAIN OUTCOME MEASURE: Cost per maternal and infant quality-adjusted life year (QALY) lost. RESULTS: Universal serological screening was superior to both screening of high-risk women and no screening (utility of -0.42, -0.63 and - 0.87 QALY lost, respectively). Sensitivity analysis demonstrated that universal screening was the most cost-effective strategy regardless of the incidence of primary infection, the acceptability of amniocentesis and the efficacy of antiviral prophylaxis. In the Monte Carlo analyses, universal serological screening was the most cost-effective option in 96.36% of simulations. Universal serological screening would allow detection of 152 cases of primary maternal CMV infection and would prevent 29 cases of congenital CMV infection annually. CONCLUSION: Our findings support the adoption of a population-based prenatal screening programme for the prevention of congenital CMV infection.
引用
- El Hachem G, Poder TG, McCarey C, et al. Prenatal Screening for CMV Primary Infection: A Cost-Utility Model. BJOG. 2025. PMID: 39895506. doi:10.1111/1471-0528.18080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。